Seeking Alpha

Hospira (HSP -1.8%) says the FDA's granted pediatric exclusivity for it's alpha-2 agonist...

Hospira (HSP -1.8%) says the FDA's granted pediatric exclusivity for it's alpha-2 agonist Precedex injection. The decision extends generic exculsivity by a period of six months after patent expiry. 
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector